A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults ...

While medications such as methadone, buprenorphine, and naltrexone are FDA-approved for treating opioid use disorder, they ...

Between 2018 and 2024, China has launched 188 domestically developed innovative drugs – nearly double the number from the ...

This article showcases a curated list of standout studies over the last week on topics such as cholesterol, GLP-1 drugs for ...

HealthDay News — Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those without ...

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

Allurion Technologies (ALUR) announced its intention to initiate a clinical study on the combination of the Allurion Balloon with GLP-1 ...

When celebrities reveal their experiences with newer weight-loss drugs, there are upsides and downsides for patients and ...

Direct-to-consumer telehealth company advertisement that aired during the Super Bowl failed to mention side effects of the drugs.

GLP-1 medications initially were used to help people with diabetes improve their insulin resistance and hunger cravings.

GLP-1 medications initially were used to help people with diabetes improve their insulin resistance and hunger cravings.

For years, conventional wisdom has been that weight loss is a matter of willpower. Those who are overweight or obese just need to try harder to eat less and exercise more. But while diet and ...